- Home
- MTUS vs ERAS Comparison
MTUS vs ERAS Comparison
Compare MTUS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTUS
- ERAS
- Stock Information
- Founded
- MTUS 1899
- ERAS 2018
- Country
- MTUS United States
- ERAS United States
- Employees
- MTUS N/A
- ERAS N/A
- Industry
- MTUS
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- MTUS
- ERAS Health Care
- Exchange
- MTUS NYSE
- ERAS Nasdaq
- Market Cap
- MTUS 699.0M
- ERAS 723.8M
- IPO Year
- MTUS N/A
- ERAS 2021
- Fundamental
- Price
- MTUS $15.79
- ERAS $2.62
- Analyst Decision
- MTUS
- ERAS Strong Buy
- Analyst Count
- MTUS 0
- ERAS 5
- Target Price
- MTUS N/A
- ERAS $5.90
- AVG Volume (30 Days)
- MTUS 442.0K
- ERAS 1.2M
- Earning Date
- MTUS 11-07-2024
- ERAS 11-12-2024
- Dividend Yield
- MTUS N/A
- ERAS N/A
- EPS Growth
- MTUS N/A
- ERAS N/A
- EPS
- MTUS 0.53
- ERAS N/A
- Revenue
- MTUS $1,171,600,000.00
- ERAS N/A
- Revenue This Year
- MTUS N/A
- ERAS N/A
- Revenue Next Year
- MTUS $8.76
- ERAS N/A
- P/E Ratio
- MTUS $29.42
- ERAS N/A
- Revenue Growth
- MTUS N/A
- ERAS N/A
- 52 Week Low
- MTUS $13.83
- ERAS $1.64
- 52 Week High
- MTUS $24.31
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- MTUS 50.19
- ERAS 42.73
- Support Level
- MTUS $15.51
- ERAS $2.51
- Resistance Level
- MTUS $17.70
- ERAS $2.68
- Average True Range (ATR)
- MTUS 0.49
- ERAS 0.21
- MACD
- MTUS -0.13
- ERAS -0.04
- Stochastic Oscillator
- MTUS 20.51
- ERAS 14.56
About MTUS METALLUS INC
Metallus Inc is an America-based manufacturer of alloy steel, as well as carbon and micro-alloy steel. The portfolio of the company includes special bar quality steel, seamless mechanical tubes, and value-add solutions, such as precision steel components. The company also supplies machining and thermal treatment services and manages raw material recycling programs that work as a feeder system for its melt operations. The company's products and services are used in the following sectors: oil and gas; automotive; industrial equipment; mining; construction; rail; aerospace and defense; heavy truck; agriculture; and power generation. Geographically, the company mainly serves customers in the United States.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.